Integration of Artificial Intelligence and CRISPR/Cas9 System for Vaccine Design.

IF 2.4 Q2 MATHEMATICAL & COMPUTATIONAL BIOLOGY

Cancer Informatics Pub Date : 2022-11-26 eCollection Date: 2022-01-01 DOI:10.1177/11769351221140102

Elham Maserat

引用次数: 1

Abstract

The CRISPR/Cas9 system offers a new approach to genome editing and cancer treatment. This approach is able to detect drug targets and genomic analysis of cancer. The use of artificial intelligence (AI) capacity to edit genomes through CRISPR/Cas9 enables modification of gene mutations, molecular simulation. AI approaches include knowledge discovery approaches, antigen and epitope prediction approaches, and agent based-model approaches. These methods in combination with CRISPR/Cas9 can be used in vaccine design.

查看原文本刊更多论文

人工智能与CRISPR/Cas9系统在疫苗设计中的集成

CRISPR/Cas9系统为基因组编辑和癌症治疗提供了一种新方法。这种方法能够检测药物靶点和癌症的基因组分析。利用人工智能(AI)能力编辑基因组，通过CRISPR/Cas9实现基因突变修饰、分子模拟。人工智能方法包括知识发现方法、抗原和表位预测方法以及基于agent的模型方法。这些方法结合CRISPR/Cas9可用于疫苗设计。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Informatics Medicine-Oncology

CiteScore

3.00

自引率

5.00%

发文量

审稿时长

8 weeks

期刊介绍： The field of cancer research relies on advances in many other disciplines, including omics technology, mass spectrometry, radio imaging, computer science, and biostatistics. Cancer Informatics provides open access to peer-reviewed high-quality manuscripts reporting bioinformatics analysis of molecular genetics and/or clinical data pertaining to cancer, emphasizing the use of machine learning, artificial intelligence, statistical algorithms, advanced imaging techniques, data visualization, and high-throughput technologies. As the leading journal dedicated exclusively to the report of the use of computational methods in cancer research and practice, Cancer Informatics leverages methodological improvements in systems biology, genomics, proteomics, metabolomics, and molecular biochemistry into the fields of cancer detection, treatment, classification, risk-prediction, prevention, outcome, and modeling.